CoChat

The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613

Open access
Remon, Jordi, Menis, Jessica, Hasan, Baktiar, Peric, Aleksandra, De Maio, Eleonora, Novello, Silvia, Reck, Martin, Berghmans, Thierry, Wasag, Bartosz, Besse, Benjamin, Dziadziuszko, Rafal · 2017 · Clinical Lung Cancer
Cited by 96

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

The AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients (APPLE) trial is a randomized, open-label, multicenter, 3-arm, phase II study in advanced, epidermal growth factor receptor ( EGFR )-mutant and EGFR tyrosine kinase inhibitor (TKI)-naive non–small-cell lung cancer (NSCLC) patients, to evaluate the best strategy for sequencing gefitinib and osimertinib treatment. Advanced EGFR -mutant NSCLC patients, with World Health Organization performance status 0-2 who are EGFR TKI treatment-naive and eligible to receive first-line treatment with EGFR TKI will be randomized to: •Arm A: osimertinib until disease progression according to Response Evaluation Criteria In Solid Tumors 1.1 (RECIST); •Arm B: gefitinib until emergence of circulating tumor DNA (ctDNA) substitution of threonine with methionine at amino acid position 790 (T790M)-positive status and then switch to osimertinib until disease progression according to RECIST; or •Arm C: gefitinib until disease progression according to RECIST and then switch to osimertinib until second radiologic disease progression. In all arms, a plasmatic ctDNA T790M test will be performed by a central laboratory at the Medical University of Gdansk (Poland) but will be applied as a predictive marker for making treatment decisions only in arm B. The primary objective is to evaluate the best strategy for sequencing of treatment with gefitinib and osimertinib in advanced NSCLC patients with common EGFR mutations, and to understand the value of liquid biopsy for the decision-making process. The progression-free survival rate at 18 months is the primary end point of the trial. The activity of osimertinib versus gefitinib to prevent brain metastases will be evaluated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cllc.2017.02.005

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 96

Metadata

Authors
Remon, J., Menis, J., Hasan, B., Peric, A., De Maio, E., Novello, S., Reck, M., Berghmans, T., Wasag, B., Besse, B., & Dziadziuszko, R.
Venue
Clinical Lung Cancer
Publisher
Elsevier BV
Published
2017-09
Volume
18
Issue
5
Pages
583-588
ISSN
1525-7304 (ISSN-L)
OpenAlex
W2594186252
Cited by
96
References
16
FWCI
11.74
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613. https://app.cochat.ai/papers/10.1016/j.cllc.2017.02.005
The paper
Remon, J., Menis, J., Hasan, B., Peric, A., De Maio, E., Novello, S., Reck, M., Berghmans, T., Wasag, B., Besse, B., & Dziadziuszko, R. (2017). The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2017.02.005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.